Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Protagonist Therapeutics, Inc. - Common Stock
(NQ:
PTGX
)
83.10
-1.69 (-1.99%)
Official Closing Price
Updated: 4:15 PM EST, Jan 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Protagonist Therapeutics, Inc. - Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Protagonist Therapeutics's Return On Capital Employed Overview
↗
March 03, 2022
Benzinga Pro data, Protagonist Therapeutics (NASDAQ:PTGX) reported Q4 sales of $8.62 million. Earnings fell to a loss of $36.91 million, resulting in a 9.18% decrease from last...
Via
Benzinga
3 Desirable Drug Stocks With Very Promising Pipelines
↗
February 16, 2022
Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider.
Via
InvestorPlace
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
↗
December 06, 2021
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...
Via
Benzinga
Analyst Ratings For Protagonist Therapeutics
↗
October 12, 2021
Analysts have provided the following ratings for Protagonist Therapeutics (NASDAQ:
Via
Benzinga
Protagonist To Go Ahead With Oral Peptide PN-235, Discontinues Phase 1 Candidate
↗
December 03, 2021
Protagonist Therapeutics Inc (NASDAQ: PTGX) has selected PN-235 (JNJ-77242113) as the final candidate for all clinical studies in multiple indications based on the...
Via
Benzinga
The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering
↗
December 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Protagonist to Discontinue Development Of Early-Stage Inflammatory Diseases...
Via
Benzinga
What 9 Analyst Ratings Have To Say About Protagonist Therapeutics
↗
November 15, 2021
Over the past 3 months, 9 analysts have published their opinion on Protagonist Therapeutics (NASDAQ:
Via
Benzinga
Why Protagonist Therapeutics Stock Skyrocketed 80.2% Last Month
↗
November 08, 2021
Following huge swings over the last two months, the biotech stock is now up 67% year to date.
Via
The Motley Fool
5 Short Squeeze Candidates To Watch: Progenity Tops List Again, Augmented Reality Play WiMi Hologram Joins List
↗
November 01, 2021
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE: GME) or AMC Entertainment Holdings Inc (NYSE: AMC). A...
Via
Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
↗
November 08, 2021
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...
Via
Benzinga
5 Short Squeeze Candidates To Watch: Progenity, Digital Brands Top List Again, SPAC AGC Joins Ahead Of Merger
↗
October 25, 2021
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE: GME) or AMC Entertainment Holdings Inc (NYSE: AMC). A...
Via
Benzinga
The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs
↗
October 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating Officer Mark Litton As Next CEO as Leen Kawas...
Via
Benzinga
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
↗
October 18, 2021
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news....
Via
Benzinga
What 10 Analyst Ratings Have To Say About Protagonist Therapeutics
↗
October 13, 2021
Analysts have provided the following ratings for Protagonist Therapeutics (NASDAQ:
Via
Benzinga
10 Biggest Price Target Changes For Wednesday
↗
October 13, 2021
MKM Partners raised the price target on Continental Resources, Inc. (NYSE:
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
October 12, 2021
Gainers NRX Pharmaceuticals (NASDAQ:NRXP...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021
↗
October 12, 2021
Upgrades For Callaway Golf Co (NYSE:ELY), Compass ...
Via
Benzinga
10 Biggest Price Target Changes For Tuesday
↗
October 12, 2021
Evercore ISI Group raised Lear Corporation (NYSE:
Via
Benzinga
46 Biggest Movers From Yesterday
↗
October 12, 2021
Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares jumped 93.9% to close at $35.36 on Monday. The FDA removed the full clinical hold on Protagonist Therapeutics’...
Via
Benzinga
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher
↗
October 11, 2021
Toward the end of trading on Monday, the Dow traded down 0.37% to 34,617.17 while the Nasdaq fell 0.05% to 34,617.14. The S&P 500 also fell, dropping 0.26% to 4,379.88. Let's look at what has happened...
Via
Talk Markets
Topics
Stocks
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher
↗
October 11, 2021
Toward the end of trading Monday, the Dow traded down 0.37% to 34,617.17 while the NASDAQ fell 0.05% to 34,617.14. The S&P also fell, dropping 0.26% to 4,379.88. The U.S. has...
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
↗
October 11, 2021
Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares increased by 92.43% to $35.1 during Monday's regular session. Trading volume for this security as of 12:30 EST is...
Via
Benzinga
Where Protagonist Therapeutics Stands With Analysts
↗
October 11, 2021
Within the last quarter, Protagonist Therapeutics (NASDAQ:PTGX) has observ...
Via
Benzinga
Mid-Day Market Update: Crude Oil Surges Over 2%; Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals
↗
October 11, 2021
Midway through trading Monday, the Dow traded up 0.50% to 34,920.55 while the NASDAQ rose 0.50% to 34,920.55. The S&P also rose, gaining 0.44% to 4,410.73. The U.S. has the...
Via
Benzinga
Topics
Stocks
28 Stocks Moving In Monday's Mid-Day Session
↗
October 11, 2021
Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares surged 85% to $33.78. The FDA removed the full clinical hold on Protagonist Therapeutics’ rusfertide clinical...
Via
Benzinga
PTGX Stock: The FDA News That Has Protagonist Therapeutics Investors Cheering Today
↗
October 11, 2021
Protagonist Therapeutics (PTGX) stock is rocketing higher on Monday thanks to an update from the FDA concerning rusfertide clinical studies.
Via
InvestorPlace
Protagonist Stock Flashes This Positive Signal After FDA Lifts Hold On Blood Diseases Drug
↗
October 11, 2021
Protagonist Therapeutics can now restart dosing patients in its rusfertide studies.
Via
Investor's Business Daily
Protagonist Shares Almost Double As FDA Lifts Clinical Hold On Rusfertide Program
↗
October 11, 2021
The FDA has removed the full clinical hold on Protagonist Therapeutics Inc's (NASDAQ: PTGX) rusfertide clinical studies. The Company provided the...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
October 11, 2021
Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares moved upwards by 89.3% to $34.53 during Monday's pre-market session. The market value of their outstanding shares is at...
Via
Benzinga
Battered Protagonist Therapeutics Stock Is Primed For a Dip-Buy
↗
October 05, 2021
When Wall Street overreacts to a news catalyst, contrarian traders can step in to take advantage of a rare opportunity now with PTGX stock.
Via
InvestorPlace
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
